SIG
SRPT icon

Senator Investment Group’s Sarepta Therapeutics SRPT Stock Holding History

Senator Investment Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100,000
Closed -$15.2M – 59
2019
Q2 		$15.2M Buy
+100,000
New +$12.2M 0.28% 49

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Senator Investment Group's SRPT Position: Q1 2023 in Review

Senator Investment Group sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 125,000 shares — an estimated $16.2M sold.

Senator Investment Group first reported a position in SRPT in Q3 2018 and held it in 5 quarters. The position peaked at $44.5M in Q1 2019. 426 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

  • Senator Investment Group reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Senator Investment Group sold 125,000 Sarepta Therapeutics shares in Q1 2023, an estimated $16.2M.
  • Senator Investment Group first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 5 quarters.
  • Senator Investment Group's Sarepta Therapeutics position peaked at $44.5M in Q1 2019.
  • 426 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on Senator Investment Group's 13F filing for Q1 2023, filed 12 May 2023.